Bryan Faust

TL;DR: The authors identified shared biology and host-directed drug targets to prioritize therapeutics with potential for rapid deployment against current and future coronavirus outbreaks, and found that individuals with genotypes corresponding to higher soluble IL17RA levels in plasma are at decreased risk of COVID-19 hospitalization.

TL;DR: Nanobodies that bind tightly to spike and efficiently neutralize SARS-CoV-2 in cells are reported, which enables aerosol-mediated delivery of this potent neutralizer directly to the airway epithelia.

TL;DR: The crystal structure of active mouse SMO in complex with the SAG21k agonist and a stabilizing intracellular binding nanobody reveals the structural basis of SMO regulation by PTCH1, and suggests a strategy for overcoming clinical resistance to SMO inhibitors.

TL;DR: In this article, a series of antibodies that potently block ACE2 binding but exhibit divergent neutralization efficacy against the live SARS-CoV-2 was discovered, and these neutralizing antibodies can inhibit or enhance Spike-mediated membrane fusion and formation of syncytia, which are associated with chronic tissue damage in individuals with COVID-19.

TL;DR: Single-domain antibodies (nanobodies) are developed that potently disrupt the interaction between the SARS-CoV-2 Spike and ACE2, promising to yield a widely deployable, patient-friendly prophylactic and/or early infection therapeutic agent to stem the worst pandemic in a century.